PFA Pension Forsikringsaktieselskab Makes New Investment in Abbott Laboratories $ABT

Key Points

• PFA Pension Forsikringsaktieselskab opened a new position in Abbott (NYSE:ABT) of 926,853 shares, worth about $116.58 million, roughly 0.05% of the company.
• Abbott beat Q1 estimates with $1.15 EPS on $11.16B revenue, set FY2026 guidance at 5.38–5.58 EPS, and announced a quarterly dividend of $0.63 (2.8% yield) payable May 15.
• About 75.2% of ABT is held by institutions; Vanguard owns roughly 175.6 million shares (~$22B), and several firms (Invesco, Capital International, AllianceBernstein) recently increased their stakes.

PFA Pension Forsikringsaktieselskab acquired a new position in shares of Abbott Laboratories (NYSE:ABT - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 926,853 shares of the healthcare product maker's stock, valued at approximately $116,580,000. PFA Pension Forsikringsaktieselskab owned about 0.05% of Abbott Laboratories as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ABT. Invesco Ltd. raised its position in shares of Abbott Laboratories by 51.0% in the third quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker's stock valued at $1,868,718,000 after buying an additional 4,713,135 shares in the last quarter. Ninety One UK Ltd acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $336,815,000. Vanguard Group Inc. raised its position in shares of Abbott Laboratories by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker's stock valued at $21,995,501,000 after buying an additional 2,402,408 shares in the last quarter. Alliancebernstein L.P. raised its position in shares of Abbott Laboratories by 51.0% in the third quarter. Alliancebernstein L.P. now owns 5,525,906 shares of the healthcare product maker's stock valued at $740,140,000 after buying an additional 1,865,250 shares in the last quarter. Finally, Capital International Investors raised its position in shares of Abbott Laboratories by 2.5% in the third quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker's stock valued at $8,251,974,000 after buying an additional 1,478,076 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Stock Down 1.4%

Shares of ABT opened at $89.51 on Friday. Abbott Laboratories has a one year low of $89.14 and a one year high of $139.06. The company has a market cap of $155.90 billion, a P/E ratio of 25.07, a P/E/G ratio of 1.51 and a beta of 0.66. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.18. The firm has a 50 day simple moving average of $104.33 and a two-hundred day simple moving average of $116.20.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating the consensus estimate of $1.14 by $0.01. The business had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The company's revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the business earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Research analysts forecast that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories's payout ratio is presently 70.59%.

Insider Activity

In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the business's stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $102,288.30. Following the sale, the executive vice president owned 146,377 shares of the company's stock, valued at approximately $16,918,253.66. The trade was a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP John A. Jr. Mccoy sold 585 shares of the business's stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the sale, the vice president directly owned 24,628 shares in the company, valued at approximately $2,846,504.24. The trade was a 2.32% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have purchased 22,200 shares of company stock valued at $2,215,100 and have sold 3,055 shares valued at $353,097. Corporate insiders own 0.46% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ABT. Mizuho dropped their price target on shares of Abbott Laboratories from $125.00 to $115.00 and set a "neutral" rating for the company in a research report on Friday, April 17th. Royal Bank Of Canada dropped their price target on shares of Abbott Laboratories from $135.00 to $130.00 and set an "outperform" rating for the company in a research report on Friday, April 17th. Raymond James Financial lowered their price objective on shares of Abbott Laboratories from $130.00 to $115.00 and set an "outperform" rating for the company in a research report on Friday, April 17th. Barclays lowered their price objective on shares of Abbott Laboratories from $144.00 to $143.00 and set an "overweight" rating for the company in a research report on Monday, April 20th. Finally, Argus lowered their price objective on shares of Abbott Laboratories from $140.00 to $125.00 and set a "buy" rating for the company in a research report on Tuesday, April 21st. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $119.43.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.